Skip to main content Skip to footer
Dhenne Avocats
  • Dhenne Avocats
  • Firm
    • Our team
    • Join us
  • Expertise
    • Expertise
    • Patents
    • UPC
    • FRAND and SEPs
    • Pharma and SPCs
    • Trade secrets
    • Saisie-contrefaçon
    • Contracts
    • Patent valuation
    • Employee inventions
    • All fields of expertise
  • Services
    • Patent litigation
    • Bringing an infringement action
    • Infringement defence
    • Invalidity action
    • Provisional measures
    • Evidence before the UPC
    • The FRAND undertaking
    • Arbitration and mediation
    • Advice:
    • Second opinion
    • Litigation readiness
    • Saisie-contrefaçon preparedness
    • Trade secret audit
    • IP due diligence
    • Local counsel in France
    • Japan and Europe
    • Defensible portfolio
    • Litigation funding
    • All services
  • Technologies
    • Technical fields
    • Electronics
    • Telecoms and FRAND
    • Pharmaceuticals
    • Medical devices
    • Chemistry
    • Biotechnology
    • Mechanical engineering
  • Publications
    • Blog
    • Kluwer Patent Blog
    • Journals and books
    • Speaking engagements
    • Patent litigation news
    • Consultation responses
    • Glossary
    • All publications
  • Le Lab
    • UPC Litigation Watch
    • UPC decisions analysed
    • UPC statistics
    • FRAND Litigation Watch
    • FRAND decisions analysed
    • Pharma Litigation Watch
    • Pharma decisions analysed
    • Subscribe to the watch
  • Contact
    • fr
    • en
    • ja
Back to blog

Category: Case Law

11 October 2026
An opt-out is not a register entry: ownership and procedural choice before the UPC
11 October 2026
An opt-out is not a register entry: ownership and procedural choice before the UPC
  • Patents
  • Litigation
  • UPC
  • Case law
7 October 2026
Patent assignment not entered in the register: the lesson of the Sony ruling
  • Patents
  • Litigation
  • Case law
  • Saisie-contrefaçon
6 October 2026
Plausibility and the right of priority: the French court faces apixaban
  • Patents
  • Litigation
  • Case law
  • Pharmaceuticals
5 October 2026
Preliminary injunctions and patent applications: the French fault line
  • Application for a preliminary injunction
  • Patents
  • Litigation
  • Case law
  • Pharmaceuticals
4 October 2026
Dosage inventions and inventive step: the strict reading of the French court
  • Patents
  • Litigation
  • Case law
  • Pharmaceuticals
25 September 2026
Unitary and National Patents: A Quest for Coherence
  • Patents
  • UPC
  • Case law
16 September 2026
G 1/25: the description as a tool for interpreting the claims
  • Patents
  • Litigation
  • UPC
  • Case law
15 September 2026
Pay-for-delay: the CJEU confirms Teva/Cephalon and defines the limits of patent settlement agreements
  • Patents
  • Litigation
  • Contract
  • Case law
  • Pharmaceuticals
14 September 2026
Valeo v. Bosch: the allocation of cases within the UPC, an alternative and not an exception
  • Patents
  • Litigation
  • Forum shopping
  • UPC
  • Case law
10 September 2026
The launch letter before the UPC: preventing urgency for generics and biosimilars
  • Application for a preliminary injunction
  • Patents
  • UPC
  • Case law
  • Pharmaceuticals
White Dhenne Avocats Logo

Patent litigation counsel.
France, Europe, UPC.

  • +33 (0)1 71 60 61 46
  • contact@dhenne-avocats.fr
  • LinkedIn
  • X ↗
  • 7, rue Commines
    75003 PARIS
© Dhenne Avocats 2026. All rights reserved.
  • Legal notice
  • Cookie policy
  • Privacy policy
  • Join us